In one of the most extensive NSCLC studies of patients with SMARCA4 mutations who received chemo-immunotherapy (CIT), Alessi et al. reported that patients with non-squamous histology who had SMARCA4 mutations (N = 114) vs. WT (N = 593) had significantly worse survival: PFS (2.7 versus 6.1 months, HR: 1.62; p < 0.001), and OS (8.1 versus 15.0 months, HR: 1.70; p < 0.001) from the start of CIT [22]. The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.